Statistics for Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials

Total visits

views
Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials 3

Total visits per month

views
mayo 2024 0
junio 2024 2
julio 2024 0
agosto 2024 1
septiembre 2024 0
octubre 2024 0
noviembre 2024 0

File Visits

views
10.1177154510970400300304.pdf 5